openPR Logo
Press release

Emerging Trends to Drive Atherosclerosis Drugs Market Growth at 3.5% CAGR Through 2029

09-15-2025 09:24 AM CET | Health & Medicine

Press release from: The Business Research Company

Atherosclerosis Drugs

Atherosclerosis Drugs

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Atherosclerosis Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of atherosclerosis drugs has been expanding progressively over recent years. It is projected to escalate from $49.89 billion in 2024 to $50.91 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 2.0%. The growth witnessed in the historic period is due to factors like cholesterol management, blood pressure control, discontinuation of smoking programs, research and development, and advances in diagnostics.

How Will the Atherosclerosis Drugs Market Size Evolve and Grow by 2029?
The market for atherosclerosis medications is predicted to experience consistent expansion in the upcoming years. It is estimated to reach "$58.36 billion by 2029 with a compound annual growth rate (CAGR) of 3.5%. The projected increase during this period can be linked to the rise in novel treatments, precision medicine, inflammation and immunotherapy, and advances in lipid management, as well as regulatory backing. Key trends anticipated for the forecast period encompass biologic treatments, gene manipulation and therapy, combined therapies, customised treatment strategies, and the use of remote monitoring and telemedicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What Drivers Are Propelling the Growth of Atherosclerosis Drugs Market Forward?
The atherosclerosis drug market's growth is projected to be spurred by the rising incidence of cardiovascular ailments. The term "cardiovascular diseases" encompasses all disorders that impact the heart and blood vessels. Atherosclerosis is characterized by an accumulation of fats, cholesterol, and other elements on an individual's arterial walls. Conditions like coronary heart disease and stroke are often the result of atherosclerosis, a circumstance where plaque builds up within the arteries. Atherosclerosis medications are employed to lessen the likelihood of adverse effects from cardiovascular diseases by managing contributing factors such as elevated cholesterol and blood clot formations. For example, in September 2024, the Minnesota Department of Health, a state health agency in the US, reported that around 30% of Minnesota's adult population (roughly 1.4 million people) were diagnosed with high blood pressure in 2023. In 2022, diseases caused by hypertension were listed as the primary or contributing cause of death for 14,225 inhabitants, accounting for nearly 28% of the state's total deaths. Consequently, the atherosclerosis drug market will expand due to the growing prevalence of cardiovascular diseases.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Emerging Trends Are Transforming the Atherosclerosis Drugs Market in 2025?
One observable trend in the atherosclerosis drugs market is the emphasis on product innovation. Major players in this market, in an effort to maintain their standing, are creating unique drugs and getting them approved. As a case in point, in March 2024, Wegovy (semaglutide) was endorsed by Novo Nordisk A/S, a health company based in Denmark, for the reduction of cardiovascular risk in individuals battling obesity or overweight problems. This novel weight loss medication, the first of its kind, is designed to mitigate the risk of serious cardiovascular events in adults with obesity or overweight instances coupled with established cardiovascular disease. This dual-purpose drug not only assists in managing obesity but also ensures significant prevention of severe cardiovascular issues thereby potentially increasing the quality of patient outcomes and life expectancy.

What Are the Key Segments in the Atherosclerosis Drugs Market?
The atherosclerosis drugs market covered in this report is segmented -

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

Who Are the Key Players Shaping the Atherosclerosis Drugs Market's Competitive Landscape?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Emerging Trends to Drive Atherosclerosis Drugs Market Growth at 3.5% CAGR Through 2029 here

News-ID: 4182311 • Views:

More Releases from The Business Research Company

Outlook for the Ready To Drink (RTD) Alcoholic Beverages Market: Major Segments, Strategic Developments, and Leading Companies
Outlook for the Ready To Drink (RTD) Alcoholic Beverages Market: Major Segments, …
The ready-to-drink (RTD) alcoholic beverages market is on track to experience significant growth over the coming years, driven by evolving consumer preferences and industry innovations. This sector is rapidly expanding as more consumers seek premium, convenient, and sustainable options in their alcoholic beverage choices. Let's explore the market's projected size, key drivers, major players, emerging trends, and segmentation details shaping its future. Projected Expansion and Market Size of the Ready To
Emerging Sub-Segments Transforming the Pumpkin Seed Protein Market Landscape
Emerging Sub-Segments Transforming the Pumpkin Seed Protein Market Landscape
The pumpkin seed protein market is emerging as a promising sector within the broader landscape of plant-based proteins. With increasing consumer interest in alternative, allergen-free protein sources and sustainable nutrition, this market is set to witness substantial growth and innovation. Let's explore the market size projections, key players, current trends, and major product segments shaping the future of pumpkin seed protein. Projected Market Valuation and Growth Expectations for Pumpkin Seed Protein
Top Players and Market Competition in the Protein Hydrolysates Industry
Top Players and Market Competition in the Protein Hydrolysates Industry
The protein hydrolysates market is positioned for significant expansion in the coming years as consumer preferences and nutritional science continue to evolve. With increasing attention on tailored nutrition solutions and the rise of plant-based options, this market is gearing up for robust growth and innovation. Protein Hydrolysates Market Size Projections Through 2030 The protein hydrolysates market is forecasted to grow substantially, reaching a value of $7.25 billion by 2030. This
Processed Meat Market Overview: Major Segments, Strategic Developments, and Leading Companies
Processed Meat Market Overview: Major Segments, Strategic Developments, and Lead …
The processed meat industry is positioned for substantial expansion over the coming years, driven by evolving consumer preferences and technological advancements. As the market adapts to changing demands and regulatory landscapes, it is expected to reach impressive valuation milestones. Let's explore the current market size, key players, emerging trends, and detailed segment analyses shaping this sector's future. Forecasted Market Size and Growth Trajectory of the Processed Meat Market The processed

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase